Drug with unique disruption of tumor blood flow shows promise
Wednesday, January 13, 2010 - 02:42
in Health & Medicine
Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).